PRESS RELEASE published on 08/25/2025 at 07:00, 1 year 2 months ago OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting OSE Immunotherapeutics announces proposed governance evolution and reaffirms strategic priorities ahead of Annual General Meeting. Company focuses on Tedopi® and Lusvertikimab to unlock full potential Strategic Priorities Governance Evolution OSE Immunotherapeutics Lusvertikimab Tedopi
BRIEF published on 08/20/2025 at 18:05, 1 year 2 months ago OSE Immunotherapeutics Appoints Thomas Gidoin as CFO Chief Financial Officer Strategic Planning Biotech Financing OSE Immunotherapeutics Thomas Gidoin
BRIEF published on 08/20/2025 at 18:05, 1 year 2 months ago OSE Immunotherapeutics nomme Thomas Gidoin au poste de directeur financier Directeur Financier Planification Stratégique OSE Immunotherapeutics Financement Des Biotechnologies Thomas Gidoin
PRESS RELEASE published on 08/20/2025 at 18:00, 1 year 2 months ago OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer OSE Immunotherapeutics appoints Thomas Gidoin as Chief Financial Officer, bringing deep expertise in capital markets and financial strategy to the company. Gidoin succeeds Anne-Laure Autret-Cornet Chief Financial Officer Capital Markets Financial Strategy OSE Immunotherapeutics Thomas Gidoin
PRESS RELEASE published on 08/20/2025 at 18:00, 1 year 2 months ago OSE Immunotherapeutics nomme Thomas Gidoin au poste de Directeur Financier Nomination de Thomas Gidoin comme nouveau Directeur Financier chez OSE Immunotherapeutics. Il apporte 15 ans d'expertise internationale en finance et gouvernance Biotechnologie Finance Directeur Financier OSE Immunotherapeutics Thomas Gidoin
BRIEF published on 07/02/2025 at 08:05, 1 year 3 months ago OSE Immunotherapeutics Updates on Legal Proceedings Transparency Shareholder Meeting Legal Proceedings OSE Immunotherapeutics Nantes Commercial Court
BRIEF published on 07/02/2025 at 08:05, 1 year 3 months ago Mises à jour d'OSE Immunotherapeutics sur les procédures judiciaires Transparence Assemblée Des Actionnaires OSE Immunotherapeutics Procédures Judiciaires Tribunal De Commerce De Nantes
PRESS RELEASE published on 07/02/2025 at 08:00, 1 year 3 months ago OSE Immunotherapeutics met à jour l’information sur les procédures en cours OSE Immunotherapeutics provides an update on ongoing legal proceedings regarding shareholders' motions, confirms plans for annual shareholders' meeting on September 30, 2025 Shareholders Biotech Annual Meeting Legal Proceedings OSE Immunotherapeutics
PRESS RELEASE published on 07/02/2025 at 08:00, 1 year 3 months ago OSE Immunotherapeutics met à jour l’information sur les procédures en cours Mise à jour des procédures en cours par OSE Immunotherapeutics concernant une action en justice et la tenue de leur assemblée générale annuelle. Vision prospective de l'entreprise Biotechnologie Procédures En Cours Déclarations Prospectives Assemblée Générale Annuelle OSE Immunotherapeutics
BRIEF published on 06/20/2025 at 19:35, 1 year 4 months ago OSE Immunotherapeutics sécurise son Assemblée Générale Actionnaires Assemblée Générale Transparence OSE Immunotherapeutics Procédures Judiciaires
Published on 10/28/2026 at 08:00, 2 hours 57 minutes ago Algo Grande Copper Makes New Skarn Discovery at Adelita; Step-Out Hole AG-CG-PH2-003 Returns a Combined 139.81 Metres of 1.3% CuEq from Cerro Grande and the New Margarita Skarn
Published on 10/28/2026 at 02:55, 8 hours 2 minutes ago Challenger Underground MRE Doubles to 230koz @ 3.65 g/t Au
Published on 10/28/2026 at 02:50, 8 hours 7 minutes ago Letter to Shareholders Regarding Annual General Meeting
Published on 10/27/2026 at 23:40, 11 hours 17 minutes ago Second Closing of US$3.4 Million Private Placement
Published on 10/27/2026 at 23:25, 11 hours 32 minutes ago Gamma Resources Announces Leadership Transition: C. Connor Messler to Become Chief Executive Officer and Gabriel Alonso-Mendoza to Become Chairman; Grants Incentive Stock Options
Published on 10/28/2026 at 10:29, 27 minutes ago The requirements trap: job ads often ask for more than necessary and hold candidates back
Published on 10/28/2026 at 10:09, 47 minutes ago Finexity AG: FINEXITY AG successfully completes 1:4 stock split
Published on 10/28/2026 at 10:00, 57 minutes ago Original-Research: Zefiro Methane Corp. (von GBC AG): BUY
Published on 10/28/2026 at 10:00, 57 minutes ago EQS Group launches Q by EQS, its intelligence layer for compliance
Published on 10/28/2026 at 09:36, 1 hour 21 minutes ago Original-Research: Villeroy & Boch AG (von Quirin Privatbank Kapitalmarktgeschäft): Buy
Published on 10/28/2026 at 08:00, 2 hours 57 minutes ago Edenred successfully raises €800 million in a dual-tranche bond offering
Published on 10/28/2026 at 08:00, 2 hours 57 minutes ago Edenred lève avec succès 800 millions d’euros dans le cadre d’une émission obligataire à deux tranches
Published on 10/27/2026 at 18:00, 16 hours 57 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 16 hours 57 minutes ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
